Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment Outcome for Head and Neck Squamous Cell Carcinoma in a Developing Country: University Malaya Medical Centre, Malaysia from 2003-2010

  • Wong, Yoke Fui (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) ;
  • Yusof, Mastura Md (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) ;
  • Ishak, Wan Zamaniah Wan (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) ;
  • Alip, Adlinda (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) ;
  • Phua, Vincent Chee Ee (Clinical Oncology Unit, Faculty of Medicine, University of Malaya)
  • Published : 2015.04.14
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Head and neck cancer (HNC) is the eighth most common cancer as estimated from worldwide data. The incidence of HNC in Peninsular Malaysia was reported as 8.5 per 100,000 population. This study was aimed to determine the treatment outcomes for HNC patients treated in the Oncology Unit of University Malaya Medical Centre (UMMC). Materials and Methods: All newly diagnosed patients with squamous cell carcinoma of head and neck (HNSCC) referred for treatment to the Oncology Unit at UMMC from 2003-2010 were retrospectively analyzed. Treatment outcomes were 5-year overall survival (OS), cause specific survival (CSS), loco-regional control (LRC) and radiotherapy (RT) related side effects. Kaplan-Meier and log rank analyses were used to determine survival outcomes, stratified according to American Joint Committee on Cancer (AJCC) stage. Results: A total of 130 cases were analysed. Most cases (81.5%) were at late stage (AJCC III-IVB) at presentation. The 5-year OS for the whole study population was 34.4% with a median follow up of 24 months. The 5-year OS according to AJCC stage was 100%, 48.2%, 41.4% and 22.0% for stage I, II, III and IVA-B, respectively. The 5-year overall CSS and LCR were 45.4% and 55.4%, respectively. Late effects of RT were documented in 41.4% of patients. The most common late effect was xerostomia. Conclusions: The treatment outcome of HNSCC at our centre is lagging behind those of developed nations. Efforts to increase the number of patients presenting in earlier stages, increase in the use of combined modality treatment, especially concurrent chemoradiotherapy and implementation of intensity modulated radiotherapy, may lead to better outcomes for our HNC patients.

Keywords

References

  1. Adelstein DJ, Li Y, Adam GL, et al (2003). An intergroup phase III comparison of standard radiationtherapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol, 21, 92-8. https://doi.org/10.1200/JCO.2003.01.008
  2. Azrif M, Jalai I, Aslan NM, et al (2011). Neoadjuvant chemotherapy for locally advanced breast cancer in a Malaysian tertiary hospital. Asian Pac J Cancer Prev, 12, 157-62.
  3. Barzan L, Talamini R, Franchin G, et al (2002). Changes in presentation and survival of head and neck carcinoma in Northeastern Italy, 1975-1998. Cancer, 95, 540-52. https://doi.org/10.1002/cncr.10682
  4. Bernat L, Hrusak D, et al (2014). Hypothyroidism after radiotherapy of headand neck cancer. J Carniomaxillofaci Surg, 42, 356-61. https://doi.org/10.1016/j.jcms.2013.09.009
  5. Bhurgri Y, Bhurgri A, Usman A, et al (2006). Epidemiological review of head and neck cancers in Karachi. Asian Pac J Cancer Prev, 7, 195-200.
  6. Browman GP, Hodson DI, Mackenzie, et al (2001). Cancer care ontario practice guideline initiative head and neck cancer disease site group. choosing a concomitant chemotherapy and radiation therapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck, 23, 579-89. https://doi.org/10.1002/hed.1081
  7. Carvalho AL, Nishimoto IN, Califano JA, et al (2005). Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer, 114, 806-16. https://doi.org/10.1002/ijc.20740
  8. Cannon DM, Geye HM, Hartig GK, et al (2013). Increased local failure risk with prolonged radiation treatment time in head and neck treated with concurrent chemotherapy. Head Neck, 36, 1120-5.
  9. Daly T, Poulsen MG, Denham JW, et al (2003). The effect of anaemia on efficacy andnormal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiotherapy Oncol J Eur Soc Therapeutic Radiology Oncol, 68, 113-22. https://doi.org/10.1016/S0167-8140(03)00198-1
  10. Denis F, Garaud P, Bardet E, et al (2004). Final results of the 94-01 french head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Clin Oncol, 22, 69-76.
  11. De Paula AM, Souza LR, Farias LC, et al (2009). Analysis of 724 cases of primary head and neck squamous cell carcinoma (HNSCC) with a focus on young patients and p53 immunolocalization. Oral Oncol, 45, 777-82. https://doi.org/10.1016/j.oraloncology.2008.11.015
  12. Dirix P, Nuyts S, Vander Poorten V, et al (2008). The influence of xerostomia after radiotherapy on quality of life: results of a questionnaire in head and neck cancer. Supportive Care Cancer, 16, 171-9. https://doi.org/10.1007/s00520-007-0300-5
  13. Forastiere AA, Goepfert H, Maor M, et al (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced larnyngeal cancer. New England J Med, 349, 2091-8. https://doi.org/10.1056/NEJMoa031317
  14. Furness S, Glenny AM, Worthington HV, et al (2011). Interventions for the treatment of oral cavity and oropharyngeal cancer: Chemotherapy (Review). Cochrane Database Syst Rev, 13, CD006386.
  15. Gupta S, Weidong K, Christopher MB, et al (2014). Impact of concomitant chemotherapy on outcomes of radiation therapy for head and neck cancer: a population based study. Int J Radiat Oncol Biol Phys, 88, 115-21. https://doi.org/10.1016/j.ijrobp.2013.09.052
  16. Jacques F, Hai-Rim S, Freddie B, et al (2008). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-010.
  17. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin I, 61, 69-90. https://doi.org/10.3322/caac.20107
  18. Jochen HL, Olga G, Robert IH, et al (2011). Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous cell cancer of the head and neck: long term results of TAX 324 randomised phase 3 trial. Lancet Oncol, 12, 153-9. https://doi.org/10.1016/S1470-2045(10)70279-5
  19. Lasrado S, Prabhu P, Kakria A, et al (2012). Clinicopathological profile of head and neck cancers in the Western development region, Nepal: a 4-year snapshot. Asian Pac J Cancer Prev, 13, 6059-62. https://doi.org/10.7314/APJCP.2012.13.12.6059
  20. MacKenzie K, Savage SA, Birchall MA (2009). Processes and outcomes of head and neck cancer patients from geographically disparate regions of the UK. a comparison of Scottish and English cohorts. Eur J SurgOncol, 35, 1113-8.
  21. Michell M, Jennifer M, Andrew T, et al (2008). Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol, 32, 3582-9.
  22. Mohanti BK, Nachiappan P, Pandey RM, et al (2007). Analysis of 2167 head and neck cancer patients' management, treatment compliance and outcomes from a regional cancer centre, Delhi, India. J Laryngol Otol, 121, 49-56.
  23. National Cancer Registry, Ministry of Health Malaysia (2006). Malaysian cancer statistics-data and figure peninsular Malaysia 2006.
  24. Nutting CM, Morden JP, Harrington KJ, et al (2011). Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomized controlled trial. Lancet Oncol, 12, 127-36. https://doi.org/10.1016/S1470-2045(10)70290-4
  25. Pierre B, Jean B, Benjamin L, et al (2013). Taxane-cisplatin fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data metaanalysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol, 31, 2854-60. https://doi.org/10.1200/JCO.2012.47.7802
  26. Pignon JP, Le Maitre A, Maillard E, et al (2009). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol, 92, 4-14. https://doi.org/10.1016/j.radonc.2009.04.014
  27. Pointreau Y, Garaud P, Chapet S, et al (2009). Randomized trial of inductionchemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larnynxpreservation. J Nat Cancer Inst, 101, 498-506. https://doi.org/10.1093/jnci/djp007
  28. Pruegssanusak K, Peereavut S, Leelamanit V, et al (2012). Survival and prognosticprognostic factors of different sites of head and neck cancer: an analysis from Thailand. Asian Pac J Cancer Prev, 13, 885-9. https://doi.org/10.7314/APJCP.2012.13.3.885
  29. Rao DN, Shroff PD, Chattopadhyay G (1998). Survival analysis of 5595 head and neck cancer-results of conventional treatment in a high-risk population. Br J Cancer, 77, 1514-8. https://doi.org/10.1038/bjc.1998.249
  30. Rusthoven K, Ballonoff A, Raben D, et al (2008). Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer, 112, 345-51. https://doi.org/10.1002/cncr.23183
  31. Sanders IW, Haslett K, Correa P, et al (2014). Sequential TPF chemotherapy followed byconcurrentchemoradiotherapy in locally advanced head and neck cancer-a retrospective analysis of toxicity and outcomes. Scottish Med J, 59, 50-5. https://doi.org/10.1177/0036933013518153
  32. Shashinder S, Choo PK, Gopala KG, et al (2008). Outcome of patients with head and neck cancers: 10-year experience of a otorhinolaryngology-head and neck unit in a tertiary hospital of a developing country. Eur J Cancer Care, 17, 93-7.
  33. Traynor AM, Richards GM, Harting GK, et al (2010). Comprehensive IMRT plus weeklycisplatin for advanced head and neck cancer: the university of Wisconsin experience. Head Neck, 32, 599-606.
  34. VanderWalde NA, Meyer AM, Deal AM, et al (2014). Effectiveness of chemoradiation for head and neck cancer in an older patient population. Int J Radiat Oncol Biol Phys, 89, 30-7. https://doi.org/10.1016/j.ijrobp.2014.01.053
  35. Van Gestel D, Van Den WD, Schrijvers D, et al (2011). Intensity-Modulated Radiotherapy in patients with head and neck cancer: a Europeon single-centre experience. Br J Radiol, 84, 367-74. https://doi.org/10.1259/bjr/67058055
  36. Van Rij CM, Oughlane-heemsbergen WD, Ackerstaff AH, et al (2008). Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiat Oncol, 3, 41. https://doi.org/10.1186/1748-717X-3-41
  37. Vila Capel A, Vilar PJ, Pedro OA, et al (2013). IMRT: preliminary results in a series of advanced head and neck cancer patients. Clin Translat Oncol, 15, 233-42. https://doi.org/10.1007/s12094-012-0911-2

Cited by

  1. Radiotherapy and Concurrent Chemo-Radiotherapy in Locally Advanced Hypopharyngeal Cancers - A Hospital Registry Based Analysis vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4723
  2. Epidemiological Study of Laryngeal Carcinoma in Western Nepal vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6541
  3. Alcohol and cigarette consumption predict mortality in patients with head and neck cancer: a pooled analysis within the International Head and Neck Cancer Epidemiology (INHANCE) Consortium vol.28, pp.11, 2017, https://doi.org/10.1093/annonc/mdx486